Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from timolol monotherapy to Ganfort or Cosopt in ocular hypertension or primary open-angle glaucoma
2010-018853-36Phase 3Completed
- Sponsor
- University of Parma
- Start
- Jul 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of bimatoprost + timolol, dorzolamide, timolol and bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by University of Parma. Primary endpoints: Diurnal intraocular pressure and Area under the curve for intraocular pressure. Started Jul 2010; status: completed.
02
Drugs
bimatoprost + timololdorzolamidetimololbimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2010-018853-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018853-36.